163 related articles for article (PubMed ID: 20846757)
21. Successful treatment of multiresistant Achromobacter xylosoxidans bacteremia in a child with acute myeloid leukemia.
Tugcu D; Turel O; Aydogan G; Akcay A; Salcioglu Z; Akici F; Sen H; Demirkaya M; Taskin N; Gurler N
Ann Saudi Med; 2015; 35(2):168-9. PubMed ID: 26336026
[TBL] [Abstract][Full Text] [Related]
22. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.
Hansen CR; Pressler T; Nielsen KG; Jensen PØ; Bjarnsholt T; Høiby N
J Cyst Fibros; 2010 Jan; 9(1):51-8. PubMed ID: 19939747
[TBL] [Abstract][Full Text] [Related]
23. Achromobacter xylosoxidans presenting as a suprapatellar abscess and polyarthritis.
Carroll MB; Forgione M
J Clin Rheumatol; 2010 Jan; 16(1):45-6. PubMed ID: 20051759
[No Abstract] [Full Text] [Related]
24. Mediastinitis superinfected by Achromobacter xylosoxidans. A case report.
Marion-Sanchez K; Lion F; Olive C; Cailleaux G; Roques F
J Infect Chemother; 2018 Dec; 24(12):987-989. PubMed ID: 29895453
[TBL] [Abstract][Full Text] [Related]
25. Clinical, microbiological profile and treatment outcome of ocular infections caused by Achromobacter xylosoxidans.
Reddy AK; Garg P; Shah V; Gopinathan U
Cornea; 2009 Dec; 28(10):1100-3. PubMed ID: 19730091
[TBL] [Abstract][Full Text] [Related]
26.
Bates AS; Natarajan M; Reddy RV
BMJ Case Rep; 2018 Nov; 11(1):. PubMed ID: 30567079
[TBL] [Abstract][Full Text] [Related]
27. A novel bacterium Achromobacter xylosoxidans as a cause of liver abscess: three case reports.
Asano K; Tada S; Matsumoto T; Miyase S; Kamio T; Sakurai K; Iida M
J Hepatol; 2005 Aug; 43(2):362-5. PubMed ID: 15978693
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of ceftiofur and cefquinome for phenotypic detection of methicillin resistance in Staphylococcus aureus using disk diffusion testing and MIC-determinations.
Aarestrup FM; Skov RL
Vet Microbiol; 2010 Jan; 140(1-2):176-9. PubMed ID: 19643555
[TBL] [Abstract][Full Text] [Related]
29. Emerging and unusual gram-negative infections in cystic fibrosis.
Davies JC; Rubin BK
Semin Respir Crit Care Med; 2007 Jun; 28(3):312-21. PubMed ID: 17562501
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens.
Saha S; Savage PB; Bal M
J Appl Microbiol; 2008 Sep; 105(3):822-8. PubMed ID: 18452533
[TBL] [Abstract][Full Text] [Related]
31. Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans.
Hu Y; Zhu Y; Ma Y; Liu F; Lu N; Yang X; Luan C; Yi Y; Zhu B
Antimicrob Agents Chemother; 2015 Feb; 59(2):1152-61. PubMed ID: 25487802
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment with doripenem of ventriculitis due to Achromobacter xylosoxidans.
Gelfand MS; Cleveland KO
QJM; 2014 Nov; 107(11):923-5. PubMed ID: 22411874
[No Abstract] [Full Text] [Related]
33. VIM-2 metallo-beta-lactamase in Achromobacter xylosoxidans in Europe.
Sofianou D; Markogiannakis A; Metzidie E; Pournaras S; Tsakris A
Eur J Clin Microbiol Infect Dis; 2005 Dec; 24(12):854-5. PubMed ID: 16333608
[No Abstract] [Full Text] [Related]
34. Perinephric abscess due to Achromobacter xylosoxidans following de-roofing of renal cyst.
Vinod V; Kumar A; Sanjeevan KV; Dinesh KR; Karim S
Surg Infect (Larchmt); 2013 Aug; 14(4):422-3. PubMed ID: 23859686
[No Abstract] [Full Text] [Related]
35. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
Saiman L; Chen Y; Tabibi S; San Gabriel P; Zhou J; Liu Z; Lai L; Whittier S
J Clin Microbiol; 2001 Nov; 39(11):3942-5. PubMed ID: 11682511
[TBL] [Abstract][Full Text] [Related]
36. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment.
Ridderberg W; Bendstrup KE; Olesen HV; Jensen-Fangel S; Nørskov-Lauritsen N
J Cyst Fibros; 2011 Dec; 10(6):466-9. PubMed ID: 21835703
[TBL] [Abstract][Full Text] [Related]
37. Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.
Warner NC; Bartelt LA; Lachiewicz AM; Tompkins KM; Miller MB; Alby K; Jones MB; Carr AL; Alexander J; Gainey AB; Daniels R; Burch AK; Brown DE; Brownstein MJ; Cheema F; Linder KE; Shields RK; Longworth S; van Duin D
Clin Infect Dis; 2021 Oct; 73(7):e1754-e1757. PubMed ID: 33313656
[TBL] [Abstract][Full Text] [Related]
38. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients.
Hogardt M; Schmoldt S; Götzfried M; Adler K; Heesemann J
J Antimicrob Chemother; 2004 Dec; 54(6):1057-61. PubMed ID: 15509615
[TBL] [Abstract][Full Text] [Related]
39. Epidemiological typing of clinical isolates of Achromobacter xylosoxidans: comparison of phenotypic and genotypic methods.
Kaur M; Ray P; Bhatty M; Sharma M
Eur J Clin Microbiol Infect Dis; 2009 Sep; 28(9):1023-32. PubMed ID: 19373499
[TBL] [Abstract][Full Text] [Related]
40. Clinical and microbiological evaluation of eight patients with isolated Achromobacter xylosoxidans.
Atalay S; Ece G; Samlioğlu P; Kose S; Maras G; Gonullu M
Scand J Infect Dis; 2012 Oct; 44(10):798-801. PubMed ID: 22404460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
